A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review)-Reference-Cited by-同舟云学术

A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review)

Published:2021-03-16 Issue:5 Volume:23 Page:
ISSN:1791-2997
Container-title:Molecular Medicine Reports
language:
Short-container-title:Mol Med Rep

Author:

Kong Xianbin¹,Lu Peng²,Liu Chuanxin³,Guo Yuzhu⁴,Yang Yuying¹,Peng Yingying¹,Wang Fangyuan¹,Bo Zhichao¹,Dou Xiaoxin¹,Shi Haoyang¹,Meng Jingyan¹

Affiliation:

1. Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China

2. State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China

3. Department of Pharmaceutical Analysis, School of Chinese Materia Medical, Beijing University of Chinese Medicine, Beijing 102488, P.R. China

4. Department of Radiotherapy, Tianjin Hospital, Tianjin 300211, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,Genetics,Molecular Biology,Molecular Medicine,Biochemistry

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engagement of CD300c by a novel monoclonal antibody induces the differentiation of monocytes to M1 macrophages;Immunobiology;2024-01

2. TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas;American Journal of Surgical Pathology;2023-12-22

3. Hot and cold tumors: Immunological features and the therapeutic strategies;MedComm;2023-08-26

4. PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers;Journal of Clinical Medicine;2023-03-03

5. Boosting Anti-tumour Immunity Using Adjuvant Apigenin;Anti-Cancer Agents in Medicinal Chemistry;2023-02